The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Bullous Pemphigoid Therapies-Global Market Insights and Sales Trends 2025

Bullous Pemphigoid Therapies-Global Market Insights and Sales Trends 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1876665

No of Pages : 110

Ask Your Query
Synopsis
Bullous pemphigoid (BP) is the most common autoimmune blistering disease in the West. Incidence figures are not available for most parts of the world but BP appears to be rarer in the Far East. Bullous pemphigoid is usually a disease of the elderly but it can also affect younger people and children. Both sexes are similarly affected.
The global Bullous Pemphigoid Therapies market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Bullous Pemphigoid Therapies in various end use industries. The expanding demands from the Initial Phase, Active Treatment Phase, Reducing Phase and Maintenance Phase, are propelling Bullous Pemphigoid Therapies market. Steroid Creams, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Immune Suppressants segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Bullous Pemphigoid Therapies, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Bullous Pemphigoid Therapies market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Bullous Pemphigoid Therapies market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Bullous Pemphigoid Therapies sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Bullous Pemphigoid Therapies covered in this report include Regeneron Pharmaceuticals, Sanofi, Pfizer, SUANFARMA, Tecoland Corporation, Century Pharmaceuticals, Akari Therapeutics, Immune Pharmaceuticals and Innate Pharma, etc.
The global Bullous Pemphigoid Therapies market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Regeneron Pharmaceuticals
Sanofi
Pfizer
SUANFARMA
Tecoland Corporation
Century Pharmaceuticals
Akari Therapeutics
Immune Pharmaceuticals
Innate Pharma
AstraZeneca
Grifols
Aptalis
Medicis Pharmaceutical Corporation
Shaanxi Xiyue Pharmaceutical
Kunming Zhenhua Pharmaceutical Factory
Qinghai Pharmaceutical Factory
Global Bullous Pemphigoid Therapies market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Bullous Pemphigoid Therapies market, Segment by Type:
Steroid Creams
Immune Suppressants
Antibiotics
Global Bullous Pemphigoid Therapies market, by Application
Initial Phase
Active Treatment Phase
Reducing Phase
Maintenance Phase
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Bullous Pemphigoid Therapies manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Bullous Pemphigoid Therapies in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index
1 Bullous Pemphigoid Therapies Market Overview
1.1 Bullous Pemphigoid Therapies Product Overview
1.2 Bullous Pemphigoid Therapies Market Segment by Type
1.2.1 Steroid Creams
1.2.2 Immune Suppressants
1.2.3 Antibiotics
1.3 Global Bullous Pemphigoid Therapies Market Size by Type
1.3.1 Global Bullous Pemphigoid Therapies Market Size Overview by Type (2018-2029)
1.3.2 Global Bullous Pemphigoid Therapies Historic Market Size Review by Type (2018-2023)
1.3.3 Global Bullous Pemphigoid Therapies Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Bullous Pemphigoid Therapies Sales Breakdown by Type (2018-2023)
1.4.2 Europe Bullous Pemphigoid Therapies Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Bullous Pemphigoid Therapies Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Bullous Pemphigoid Therapies Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Bullous Pemphigoid Therapies Sales Breakdown by Type (2018-2023)
2 Global Bullous Pemphigoid Therapies Market Competition by Company
2.1 Global Top Players by Bullous Pemphigoid Therapies Sales (2018-2023)
2.2 Global Top Players by Bullous Pemphigoid Therapies Revenue (2018-2023)
2.3 Global Top Players by Bullous Pemphigoid Therapies Price (2018-2023)
2.4 Global Top Manufacturers Bullous Pemphigoid Therapies Manufacturing Base Distribution, Sales Area, Product Type
2.5 Bullous Pemphigoid Therapies Market Competitive Situation and Trends
2.5.1 Bullous Pemphigoid Therapies Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Bullous Pemphigoid Therapies Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Bullous Pemphigoid Therapies as of 2022)
2.7 Date of Key Manufacturers Enter into Bullous Pemphigoid Therapies Market
2.8 Key Manufacturers Bullous Pemphigoid Therapies Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Bullous Pemphigoid Therapies Status and Outlook by Region
3.1 Global Bullous Pemphigoid Therapies Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Bullous Pemphigoid Therapies Historic Market Size by Region
3.2.1 Global Bullous Pemphigoid Therapies Sales in Volume by Region (2018-2023)
3.2.2 Global Bullous Pemphigoid Therapies Sales in Value by Region (2018-2023)
3.2.3 Global Bullous Pemphigoid Therapies Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Bullous Pemphigoid Therapies Forecasted Market Size by Region
3.3.1 Global Bullous Pemphigoid Therapies Sales in Volume by Region (2024-2029)
3.3.2 Global Bullous Pemphigoid Therapies Sales in Value by Region (2024-2029)
3.3.3 Global Bullous Pemphigoid Therapies Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Bullous Pemphigoid Therapies by Application
4.1 Bullous Pemphigoid Therapies Market Segment by Application
4.1.1 Initial Phase
4.1.2 Active Treatment Phase
4.1.3 Reducing Phase
4.1.4 Maintenance Phase
4.2 Global Bullous Pemphigoid Therapies Market Size by Application
4.2.1 Global Bullous Pemphigoid Therapies Market Size Overview by Application (2018-2029)
4.2.2 Global Bullous Pemphigoid Therapies Historic Market Size Review by Application (2018-2023)
4.2.3 Global Bullous Pemphigoid Therapies Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Bullous Pemphigoid Therapies Sales Breakdown by Application (2018-2023)
4.3.2 Europe Bullous Pemphigoid Therapies Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Bullous Pemphigoid Therapies Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Bullous Pemphigoid Therapies Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Bullous Pemphigoid Therapies Sales Breakdown by Application (2018-2023)
5 North America Bullous Pemphigoid Therapies by Country
5.1 North America Bullous Pemphigoid Therapies Historic Market Size by Country
5.1.1 North America Bullous Pemphigoid Therapies Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Bullous Pemphigoid Therapies Sales in Volume by Country (2018-2023)
5.1.3 North America Bullous Pemphigoid Therapies Sales in Value by Country (2018-2023)
5.2 North America Bullous Pemphigoid Therapies Forecasted Market Size by Country
5.2.1 North America Bullous Pemphigoid Therapies Sales in Volume by Country (2024-2029)
5.2.2 North America Bullous Pemphigoid Therapies Sales in Value by Country (2024-2029)
6 Europe Bullous Pemphigoid Therapies by Country
6.1 Europe Bullous Pemphigoid Therapies Historic Market Size by Country
6.1.1 Europe Bullous Pemphigoid Therapies Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Bullous Pemphigoid Therapies Sales in Volume by Country (2018-2023)
6.1.3 Europe Bullous Pemphigoid Therapies Sales in Value by Country (2018-2023)
6.2 Europe Bullous Pemphigoid Therapies Forecasted Market Size by Country
6.2.1 Europe Bullous Pemphigoid Therapies Sales in Volume by Country (2024-2029)
6.2.2 Europe Bullous Pemphigoid Therapies Sales in Value by Country (2024-2029)
7 Asia-Pacific Bullous Pemphigoid Therapies by Region
7.1 Asia-Pacific Bullous Pemphigoid Therapies Historic Market Size by Region
7.1.1 Asia-Pacific Bullous Pemphigoid Therapies Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Bullous Pemphigoid Therapies Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Bullous Pemphigoid Therapies Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Bullous Pemphigoid Therapies Forecasted Market Size by Region
7.2.1 Asia-Pacific Bullous Pemphigoid Therapies Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Bullous Pemphigoid Therapies Sales in Value by Region (2024-2029)
8 Latin America Bullous Pemphigoid Therapies by Country
8.1 Latin America Bullous Pemphigoid Therapies Historic Market Size by Country
8.1.1 Latin America Bullous Pemphigoid Therapies Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Bullous Pemphigoid Therapies Sales in Volume by Country (2018-2023)
8.1.3 Latin America Bullous Pemphigoid Therapies Sales in Value by Country (2018-2023)
8.2 Latin America Bullous Pemphigoid Therapies Forecasted Market Size by Country
8.2.1 Latin America Bullous Pemphigoid Therapies Sales in Volume by Country (2024-2029)
8.2.2 Latin America Bullous Pemphigoid Therapies Sales in Value by Country (2024-2029)
9 Middle East and Africa Bullous Pemphigoid Therapies by Country
9.1 Middle East and Africa Bullous Pemphigoid Therapies Historic Market Size by Country
9.1.1 Middle East and Africa Bullous Pemphigoid Therapies Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Bullous Pemphigoid Therapies Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Bullous Pemphigoid Therapies Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Bullous Pemphigoid Therapies Forecasted Market Size by Country
9.2.1 Middle East and Africa Bullous Pemphigoid Therapies Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Bullous Pemphigoid Therapies Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Regeneron Pharmaceuticals
10.1.1 Regeneron Pharmaceuticals Company Information
10.1.2 Regeneron Pharmaceuticals Introduction and Business Overview
10.1.3 Regeneron Pharmaceuticals Bullous Pemphigoid Therapies Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Regeneron Pharmaceuticals Bullous Pemphigoid Therapies Products Offered
10.1.5 Regeneron Pharmaceuticals Recent Development
10.2 Sanofi
10.2.1 Sanofi Company Information
10.2.2 Sanofi Introduction and Business Overview
10.2.3 Sanofi Bullous Pemphigoid Therapies Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Sanofi Bullous Pemphigoid Therapies Products Offered
10.2.5 Sanofi Recent Development
10.3 Pfizer
10.3.1 Pfizer Company Information
10.3.2 Pfizer Introduction and Business Overview
10.3.3 Pfizer Bullous Pemphigoid Therapies Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Pfizer Bullous Pemphigoid Therapies Products Offered
10.3.5 Pfizer Recent Development
10.4 SUANFARMA
10.4.1 SUANFARMA Company Information
10.4.2 SUANFARMA Introduction and Business Overview
10.4.3 SUANFARMA Bullous Pemphigoid Therapies Sales, Revenue and Gross Margin (2018-2023)
10.4.4 SUANFARMA Bullous Pemphigoid Therapies Products Offered
10.4.5 SUANFARMA Recent Development
10.5 Tecoland Corporation
10.5.1 Tecoland Corporation Company Information
10.5.2 Tecoland Corporation Introduction and Business Overview
10.5.3 Tecoland Corporation Bullous Pemphigoid Therapies Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Tecoland Corporation Bullous Pemphigoid Therapies Products Offered
10.5.5 Tecoland Corporation Recent Development
10.6 Century Pharmaceuticals
10.6.1 Century Pharmaceuticals Company Information
10.6.2 Century Pharmaceuticals Introduction and Business Overview
10.6.3 Century Pharmaceuticals Bullous Pemphigoid Therapies Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Century Pharmaceuticals Bullous Pemphigoid Therapies Products Offered
10.6.5 Century Pharmaceuticals Recent Development
10.7 Akari Therapeutics
10.7.1 Akari Therapeutics Company Information
10.7.2 Akari Therapeutics Introduction and Business Overview
10.7.3 Akari Therapeutics Bullous Pemphigoid Therapies Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Akari Therapeutics Bullous Pemphigoid Therapies Products Offered
10.7.5 Akari Therapeutics Recent Development
10.8 Immune Pharmaceuticals
10.8.1 Immune Pharmaceuticals Company Information
10.8.2 Immune Pharmaceuticals Introduction and Business Overview
10.8.3 Immune Pharmaceuticals Bullous Pemphigoid Therapies Sales, Revenue and Gross Margin (2018-2023)
10.8.4 Immune Pharmaceuticals Bullous Pemphigoid Therapies Products Offered
10.8.5 Immune Pharmaceuticals Recent Development
10.9 Innate Pharma
10.9.1 Innate Pharma Company Information
10.9.2 Innate Pharma Introduction and Business Overview
10.9.3 Innate Pharma Bullous Pemphigoid Therapies Sales, Revenue and Gross Margin (2018-2023)
10.9.4 Innate Pharma Bullous Pemphigoid Therapies Products Offered
10.9.5 Innate Pharma Recent Development
10.10 AstraZeneca
10.10.1 AstraZeneca Company Information
10.10.2 AstraZeneca Introduction and Business Overview
10.10.3 AstraZeneca Bullous Pemphigoid Therapies Sales, Revenue and Gross Margin (2018-2023)
10.10.4 AstraZeneca Bullous Pemphigoid Therapies Products Offered
10.10.5 AstraZeneca Recent Development
10.11 Grifols
10.11.1 Grifols Company Information
10.11.2 Grifols Introduction and Business Overview
10.11.3 Grifols Bullous Pemphigoid Therapies Sales, Revenue and Gross Margin (2018-2023)
10.11.4 Grifols Bullous Pemphigoid Therapies Products Offered
10.11.5 Grifols Recent Development
10.12 Aptalis
10.12.1 Aptalis Company Information
10.12.2 Aptalis Introduction and Business Overview
10.12.3 Aptalis Bullous Pemphigoid Therapies Sales, Revenue and Gross Margin (2018-2023)
10.12.4 Aptalis Bullous Pemphigoid Therapies Products Offered
10.12.5 Aptalis Recent Development
10.13 Medicis Pharmaceutical Corporation
10.13.1 Medicis Pharmaceutical Corporation Company Information
10.13.2 Medicis Pharmaceutical Corporation Introduction and Business Overview
10.13.3 Medicis Pharmaceutical Corporation Bullous Pemphigoid Therapies Sales, Revenue and Gross Margin (2018-2023)
10.13.4 Medicis Pharmaceutical Corporation Bullous Pemphigoid Therapies Products Offered
10.13.5 Medicis Pharmaceutical Corporation Recent Development
10.14 Shaanxi Xiyue Pharmaceutical
10.14.1 Shaanxi Xiyue Pharmaceutical Company Information
10.14.2 Shaanxi Xiyue Pharmaceutical Introduction and Business Overview
10.14.3 Shaanxi Xiyue Pharmaceutical Bullous Pemphigoid Therapies Sales, Revenue and Gross Margin (2018-2023)
10.14.4 Shaanxi Xiyue Pharmaceutical Bullous Pemphigoid Therapies Products Offered
10.14.5 Shaanxi Xiyue Pharmaceutical Recent Development
10.15 Kunming Zhenhua Pharmaceutical Factory
10.15.1 Kunming Zhenhua Pharmaceutical Factory Company Information
10.15.2 Kunming Zhenhua Pharmaceutical Factory Introduction and Business Overview
10.15.3 Kunming Zhenhua Pharmaceutical Factory Bullous Pemphigoid Therapies Sales, Revenue and Gross Margin (2018-2023)
10.15.4 Kunming Zhenhua Pharmaceutical Factory Bullous Pemphigoid Therapies Products Offered
10.15.5 Kunming Zhenhua Pharmaceutical Factory Recent Development
10.16 Qinghai Pharmaceutical Factory
10.16.1 Qinghai Pharmaceutical Factory Company Information
10.16.2 Qinghai Pharmaceutical Factory Introduction and Business Overview
10.16.3 Qinghai Pharmaceutical Factory Bullous Pemphigoid Therapies Sales, Revenue and Gross Margin (2018-2023)
10.16.4 Qinghai Pharmaceutical Factory Bullous Pemphigoid Therapies Products Offered
10.16.5 Qinghai Pharmaceutical Factory Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Bullous Pemphigoid Therapies Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Bullous Pemphigoid Therapies Industrial Chain Analysis
11.4 Bullous Pemphigoid Therapies Market Dynamics
11.4.1 Bullous Pemphigoid Therapies Industry Trends
11.4.2 Bullous Pemphigoid Therapies Market Drivers
11.4.3 Bullous Pemphigoid Therapies Market Challenges
11.4.4 Bullous Pemphigoid Therapies Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Bullous Pemphigoid Therapies Distributors
12.3 Bullous Pemphigoid Therapies Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock